All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CERC-002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Cerecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 29, 2021
Details:
ERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphocytes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rhSP-D
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-100
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2021
Details:
AT-100 is a novel human recombinant protein that has been shown in preclinical studies to reduce inflammation and infection triggered in very preterm babies by mechanical ventilation and oxygen support and ultimately reduce the onset of lung damage.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AV-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AV-001
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
Details:
It analysed the safety, tolerability and pharmacokinetics of AV-001 following administration of single-ascending and multiple-ascending doses up to 56µg/kg a day for seven consecutive days.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TDI01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TDI01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Graviton
Deal Size: $517.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 23, 2021
Details:
The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
